Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081153 · ClinicalTrials.gov registry record · Early Phase 1
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
NCT06081153: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT06081153 is a Early Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06081153, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.
Interventions
- DRUG Placebo
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2029-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06081153
The ClinicalTrials.gov registry entry for NCT06081153 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06081153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06081153 about?
NCT06081153 is a clinical study titled "Mechanistic Clinical Trial of PCSK9 Inhibition for AAA". The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers wil...
What is the current status of trial NCT06081153?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2026-12-01. Estimated completion is 2029-02-28.
What interventions are being tested in trial NCT06081153?
The interventions under investigation include: Placebo (DRUG), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT06081153?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.